Glaser Weil Represents TriMed in Sale of Majority Interest to Henry Schein

Glaser Weil represented TriMed Inc., a global developer of market-leading orthopedic implants, in the sale of a majority interest to Henry Schein, Inc. (NASDAQ: HSIC), the world’s largest provider of health care solutions to office-based dental and medical practitioners.

The deal was announced on December 20, 2023, and completed on April 4, 2024.

The Glaser Weil deal team was led by George Wall, partner and chair of the mergers and acquisitions practice, and included partners Matthew Jann and Jeffrey Soza and associates Gabriel Kiss and Lara Petersen.

For more information, read the press release.